Dongkook Pharmaceutical "In Commemoration of International Women's Day, Selected 7 Major Pharmaceuticals"

Dongkook Pharmaceutical announced on the 8th, in celebration of 'International Women's Day,' that it has selected representative pharmaceuticals aimed at improving women's health and quality of life.

The selected pharmaceuticals include ▲ the female menopause treatment 'FemarinQ' ▲ the venous circulation disorder improvement agent 'Sincia' ▲ the anti-malignant tumor agent 'Lorelindeppo' ▲ the endometriosis treatment 'Loraen Tablets' ▲ the postmenopausal symptom improvement hormone drug 'Tibolan Tablets' ▲ the hyaluronic acid filler 'Bellast' ▲ and the TECA-applied cosmetics 'Centellian24.'

Prescription drugs and beauty products from Dongkook Pharmaceutical. [Photo by Dongkook Pharmaceutical]

Lorelindeppo is an anti-malignant tumor agent that shows therapeutic effects with just one monthly administration for endometriosis, uterine fibroids, premenopausal breast cancer, prostate cancer, and central precocious puberty. Dongkook Pharmaceutical was the first in Korea and the second in the world to successfully commercialize this product in 1997. It is a pharmaceutical product patented for its 'porous and non-porous microparticle-based long-acting release technology' that does not contain gelatin, with patents obtained in the United States and the United Kingdom, and it is registered and approved in more than 10 countries overseas.

Loraen Tablets are used as an endometriosis treatment with follicle-stimulating hormone and luteinizing hormone. Tibolan Tablets are white, oblong tablets that regulate the action of sex hormones in the body to improve postmenopausal symptoms such as hot flashes and osteoporosis.

‘Lunit Insight MMG’ by Dongkook Life Science, established in May 2017 through a physical division from Dongkook Pharmaceutical, is an AI (artificial intelligence) medical company Lunit’s imaging analysis solution that detects breast cancer findings in mammography images. It analyzes big data of breast cancer diseases and assists radiologists’ interpretations using AI technology. This helps increase the accuracy of breast cancer diagnosis and aids in early detection of breast cancer patients. Dongkook Life Science has formed a strategic partnership with Hologic, a global company in the field of imaging diagnostics, and plans to expand its lineup of medical equipment for women’s health, including digital mammography devices and biopsy-specific mammography equipment.

Additionally, Dongkook Pharmaceutical has actively promoted awareness and the need for management of related diseases through the 'Know Your Disease Campaign' targeting consumers for over-the-counter drugs such as FemarinQ and Sincia. The company has also launched wrinkle-improving fillers like Bellast and cosmetics such as Centellian24 for women’s beauty.

A representative from Dongkook Pharmaceutical stated, "We will continue to deepen our understanding of health issues faced by women and expand our research and development (R&D) pipeline in areas such as female skin beauty and hair loss, overactive bladder treatment, endometriosis treatment, and breast cancer treatment through continuous research and development."